...
首页> 外文期刊>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research >Inhibition of BMP receptor synthesis by antisense oligonucleotides attenuates OP-1 action in primary cultures of fetal rat calvaria cells.
【24h】

Inhibition of BMP receptor synthesis by antisense oligonucleotides attenuates OP-1 action in primary cultures of fetal rat calvaria cells.

机译:反义寡核苷酸对BMP受体合成的抑制作用会减弱胎儿大鼠颅盖细胞原代培养物中的OP-1作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Osteogenic protein-1 (OP-1 or bone morphogenetic protein-7 [BMP-7]) stimulates osteoblast differentiation in vitro and induces bone formation in vivo. BMPs exert their effects through complex formation with a heterodimeric receptor composed of a type I and a type II polypeptide. In the present study, mRNAs for three BMP subtype I receptors (ActR-I, BMPR-IA, and BMPR-IB) and one BMPR-II receptor were detected by Northern analysis in two human osteosarcoma cell lines (SaOS-2 and TE85) and in the primary cultures of fetal rat calvaria (FRC) cells. OP-1 affected the steady-state mRNA levels of these receptors differently among these cell types. To study the role of each receptor type in OP-1 action in FRC cells, receptor synthesis was inhibited by antisense oligonucleotides. Inhibition of receptor synthesis was confirmed by immunoprecipitation of radiolabeled cellular proteins with specific antibodies. The osteogenic action of OP-1 was measured by alkaline phosphatase (ALP) activity and mineralized bone nodule formation in FRC cells. Results showed that inhibition of synthesis of a single subtype I receptor alone did not affect significantly the OP-1-stimulated ALP activity. Inhibition of BMPR-II synthesis reduced the OP-1-stimulated ALP activity by about 50%. Inhibition of synthesis of any one of the type I receptor plus the BMPR-II receptor did not reduce the OP-1-stimulated ALP activity significantly beyond that observed by inhibition of BMPR-II alone. Under these conditions, nodule formation was affected similarly, thus supporting the observations made with the ALP measurements. The present results suggest that the ActR-I, BMPR-IA, and BMPR-IB receptors and the BMPR-II receptor are expressed and functional for OP-1 in FRC cells and that regulation of synthesis of these receptors may be a mechanism by which a specific cell type responds to OP-1. The turnover rate of these receptor proteins might be relatively long and another type II receptor(s) for OP-1 might be functional in FRC cells.
机译:成骨蛋白1(OP-1或骨形态发生蛋白7 [BMP-7])在体外刺激成骨细胞分化并在体内诱导骨形成。 BMP通过与由I型和II型多肽组成的异二聚体受体形成复合物来发挥作用。在本研究中,通过Northern分析在两种人骨肉瘤细胞系(SaOS-2和TE85)中检测到了三种BMP I型受体(ActR-I,BMPR-IA和BMPR-IB)和一种BMPR-II受体的mRNA。以及胎鼠颅盖(FRC)细胞的原代培养。在这些细胞类型中,OP-1对这些受体的稳态mRNA水平的影响不同。为了研究每种受体类型在FRC细胞中OP-1作用中的作用,受体合成被反义寡核苷酸抑制。通过用特异性抗体免疫沉淀放射性标记的细胞蛋白来确认受体合成的抑制。 OP-1的成骨作用通过碱性磷酸酶(ALP)活性和FRC细胞中矿化的骨结节形成来测量。结果表明,单独抑制单个亚型I受体的合成不会显着影响OP-1刺激的ALP活性。抑制BMPR-II合成可使OP-1刺激的ALP活性降低约50%。抑制I型受体加BMPR-II受体中的任何一种的合成,均不能使OP-1刺激的ALP活性显着降低,而不能单独抑制BMPR-II。在这些条件下,结节的形成也受到类似的影响,从而支持了ALP测量的观察结果。目前的结果表明ActR-I,BMPR-IA和BMPR-IB受体以及BMPR-II受体在FRC细胞中对OP-1表达并具有功能,而调节这些受体的合成可能是一种机制。特定的单元格类型会响应OP-1。这些受体蛋白的更新率可能相对较长,OP-1的另一种II型受体可能在FRC细胞中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号